tirzepatide and gut health in Houston: Weight Loss Program How Tirzepatide Helps Lose Weight

For patients with BED who also have obesity or type 2 diabetes, tirzepatide could theoretically address multiple therapeutic targets simultaneously

Between 2005 and 2021, the following GLP-1 agonists were also approved by the FDA for parenteral use: liraglutide, albiglutide, lixisenatide, dulaglutide, and semaglutide

Slow digestion from GLP-1 may impact how fast levothyroxine is absorbed

It is expected to become a new target for the treatment of metabolic disorders

The relationship between the gutbrainsleep axis and hormonal regulation helps explain why GLP-1 signaling capacity can vary significantly across individuals, even those with similar microbial profiles

Combining adequate protein intake (0.7 to 1.0 grams per pound of ideal body weight) with resistance training 2 to 3 times per week is the most effective strategy for ensuring that weight loss comes from fat rather than muscle